Summit Therapeutics Balance Sheet Health
Financial Health criteria checks 5/6
Summit Therapeutics has a total shareholder equity of $437.9M and total debt of $24.5M, which brings its debt-to-equity ratio to 5.6%. Its total assets and total liabilities are $502.9M and $64.9M respectively.
Key information
5.6%
Debt to equity ratio
US$24.50m
Debt
| Interest coverage ratio | n/a |
| Cash | US$486.90m |
| Equity | US$437.92m |
| Total liabilities | US$64.93m |
| Total assets | US$502.85m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: SMMT *'s short term assets ($490.3M) exceed its short term liabilities ($59.0M).
Long Term Liabilities: SMMT *'s short term assets ($490.3M) exceed its long term liabilities ($5.9M).
Debt to Equity History and Analysis
Debt Level: SMMT * has more cash than its total debt.
Reducing Debt: SMMT *'s debt to equity ratio has increased from 0% to 5.6% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SMMT * has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: SMMT * has sufficient cash runway for 2.4 years if free cash flow continues to reduce at historical rates of 42.9% each year.